CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

CDMO Subsection

Insights into the latest developments in CDMO services and manufacturing.

Continue reading

Injectables Subsection

Expert perspectives on the evolving needs of injectable therapies and packaging.

Continue reading

Nasal & Pulmonary Subsection

Exploring the latest developments in inhalation technologies, respiratory delivery and sustainability

Continue reading

Advertisement

CPHI Milan
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Lifecore Biomedical

Advertisement

Solstice

SMi Presents their 2nd Annual: Highly Potent Active Pharmaceutical Ingredients (HPAPI)

Date: 21st – 22nd May 2018
Workshop: 23rd May 2018
Location: Holiday Inn, Kensington Forum, London, UK
Website: www.highlypotentapi.com/ipi
About HPAPI
SMi is delighted to announce its 2nd Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 21st – 22nd May 2018.
The global market for Highly Potent Active Pharmaceutical Ingredients is currently on a growth fast track, largely driven by its major use in oncology for cancer treatment and more often in the form of ADCs. Over a quarter of drugs worldwide now contain HPAPIs, as they have proven to be more effective than other APIs.
However, working with APIs high in potency and cytotoxicity comes with many regulations and requirements, and presents pharmaceutical companies with challenges such as handling, containment, cost and security questions.
This conference will cover many important and in-demand aspects of the HPAPI industry, creating a networking platform for industry professionals and key players to share their knowledge and find new innovative solutions.
How Will You Benefit?
Network and learn from leading professionals such as:
CHAIR FOR 2018:
Justin Mason-Home, Director, HPAPI Project Services Limited
KEY SPEAKERS INCLUDE:

  • Ildikó Zeigler, Validation Expert, Gedeon Richter
  • Ulrich Ruemenapp, Head of Launch Preparation and Coordination, Bayer
  • Vincenzo De Sio, HPAPI Specialist, Cristália
  • Pascal Drago, Principal Technical Manager, Roche
  • Henri Motte, Head of Pilot Plant, UCB Pharma
  • Jeff Parry, Senior Scientist Manufacturability, AstraZeneca
  • Greg Sowell, Principal Scientific Manager, Genentech

FEATURED HIGHLIGHTS:

  • Discover practical approaches to HPAPI manufacturing in a controlled and efficient manner
  • Explore different containment methods and learn about which strategy best suits your needs
  • Evaluate the use of containment risk mitigation tools in early phase development
  • Learn how to manage and effectively and safely dispose of HPAPI, post-production waste
  • Discuss the most important regulations surrounding potent ingredients

View the full agenda: www.highlypotentapi.com/ipi

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Tjoapack
Aptar – 08/01/2026